CIMZIA (CERTOLIZUMAB PEGOL) (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023
Cimzia (certolizumab pegol) (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023

The table below provides the key metrics for Cimzia (certolizumab pegol) in the 10MM (US, France, Germany, Italy, Spain, UK, Japan, Australia, India and China) during the forecast period from 2013–2023.

### Cimzia (certolizumab pegol): Key Metrics in the 10MM for Rheumatoid Arthritis, 2013–2023

<table>
<thead>
<tr>
<th>2013 Market Sales</th>
<th>Sales</th>
</tr>
</thead>
<tbody>
<tr>
<td>US</td>
<td>$323.7m</td>
</tr>
<tr>
<td>5EU</td>
<td>$181.1m</td>
</tr>
<tr>
<td>Japan</td>
<td>$53.4m</td>
</tr>
<tr>
<td>Australia</td>
<td>$16.6m</td>
</tr>
<tr>
<td>China</td>
<td>N/A</td>
</tr>
<tr>
<td>India</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$574.8m</strong></td>
</tr>
</tbody>
</table>

### Key Events (2013–2023)

<table>
<thead>
<tr>
<th>Level of Impact</th>
</tr>
</thead>
<tbody>
<tr>
<td>Launch of biosimilars of certolizumab pegol across the US in 2021</td>
</tr>
<tr>
<td>Patent expiry/ Launch of certolizumab pegol biosimilars across Japan in 2023</td>
</tr>
<tr>
<td>Patent expiry/ Launch of certolizumab pegol biosimilars across the 5EU in 2021</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2023 Market Sales</th>
<th>Sales</th>
</tr>
</thead>
<tbody>
<tr>
<td>US</td>
<td>$192.1m</td>
</tr>
<tr>
<td>5EU</td>
<td>$179.7m</td>
</tr>
<tr>
<td>Japan</td>
<td>$75.6m</td>
</tr>
<tr>
<td>Australia</td>
<td>$33.5m</td>
</tr>
<tr>
<td>China</td>
<td>$17.8m</td>
</tr>
<tr>
<td>India</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$498.8m</strong></td>
</tr>
</tbody>
</table>

Source: GlobalData

Cimzia (certolizumab pegol) in the Rheumatoid Arthritis Market

Cimzia (certolizumab pegol) sales are expected to decrease from $574.8 million in 2013 to $498.8 million in 2023 with a negative Compound Annual Growth Rate (CAGR) of 1.4%.

Major drivers for the growth of Cimzia (certolizumab pegol) in the RA market during the forecast period are:

- Discount is offered in the UK and for qualifying patients in the US, which means it has captured part of the market that is more price-sensitive.
- Potential to expand RA label to include DMARD-naïve patients with early active RA, as indicated by the trial design of the C-EARLY study.
- Potential to expand RA label to include inhibition of structural damage, as shown in the RAPID1 study.
- Potential to demonstrate non-inferiority to the leading first-line biologic, Humira, based on the ongoing head-to-head EXXELERATE study.
- Cimzia Co-pay Savings Card (CIMplicity) program allows patients who qualify savings on their Cimzia prescription.
Executive Summary

Major barriers to the growth of Cimzia (certolizumab pegol) in the RA market are:

- A new oral therapy, Pfizer’s Xeljanz, was recently introduced to the RA market, and other oral JAK inhibitors in the late-stage pipeline are forecast to enter the market over the next decade, all of which will be competing with the anti-TNFs.

- Lack of physician familiarity may limit uptake.

- The market entry of pipeline biologic therapies, such as anti-IL-6 biologics (sarilumab, sirukumab, clazakizumab) and other drugs with novel mechanisms of action (including tregalizumab and Cosentyx), will provide additional options for physicians when they require a biologic therapy.

The figure below shows the sales for Cimzia (certolizumab pegol) in the 10MM by region during the forecast period.
**Executive Summary**

**What do the Physicians Think?**

The RA market is very competitive, and the new entrants are expected to be met with some resistance and experience slow uptake, as the market is currently dominated by the anti-TNFs, and rheumatologists feel comfortable with the long-term safety and efficacy of this class of drugs.

“We at least have a reasonably good handle on what the long-term or relatively long-term safety profile of [the] anti-TNFs is. They’re not perfect, but at least we know what the issues are, and there are concerns, I think, with the [the] long-term safety profiles of some of the new agents that have come through. And so, given that we rheumatologists feel more comfortable with the anti-TNFs..., we know what to look out for. Then, for any new players..., it can be difficult to compete because the concern is always, well, maybe the new drug might have long-term side effects, and so we better use the ones that we’ve got more — [that] we’re more familiar with.”

[EU] KOL

“This unless we can upfront identify a group in whom it’s [a pipeline agent] going to be effective..., [or] unless it’s marketed at a significantly lower cost than its competitors, what will happen is that the [new] drug will be used fourth or fifth line, etcetera. Because if it costs the same as a currently available biologic, the currently available biologics have got a stronger history, [a] longer history of maybe safety and efficacy data, [so] why would you choose to use the new one unless you’d actually tried and failed [with] the old ones? The problem with that, of course, for the new ones, is that they end up being tried on often the most difficult rheumatoid [arthritis] patients, and so, often they don’t work.”

[EU] KOL

One of the greatest challenges with the introduction of new biologics in the RA market will be to target these drugs to the right patients. Many rheumatologists believe that the future of RA is in individualized medicine, where biomarkers determine the best course of action for each patient.
Executive Summary

“I think the patients find the whole process [of finding an effective therapy to be] very difficult. They often lose faith in our approach to treat their disease well. It may have an impact on their adherence to medication in the future. We kind of keep dropping and changing between one thing and another thing. How do they know that the fifth thing is going to work when the first four haven’t? Actually, adherence to drugs is a big issue in people with long-term conditions [such as RA], and the fact that it can take us a long time to find something that works, I think, is a big issue in the context of that for the patients as well.”

[UK] KOL

“I think it will be very difficult for rheumatologists to manage this huge number of different drugs that are available without us having some kind of strategy for establishing which groups of patients each particular drug would be most effective in, and so that kind of takes us down to [the] personalized medicine route, and I think that’s what companies need to be looking at as they’re developing these new agents….We need to work out who to treat with what — who to treat with what drug, based on identifying biomarkers that predict [the patient’s] response, which could be ones that you measure in the blood or [the] ones that you measure from the joint, but I think that will have to be the direction of travel.”

[EU] KOL

One of the greatest unmet needs in RA is the affordability of drugs, as the biologics cost upwards of $30,000 per year in the US. Biosimilars are expected to launch over the forecast period from 2013–2023 in all 10 markets covered in this report, changing the market dynamics and offering a less expensive alternative to the branded biologics.

“If a biosimilar is only half as expensive [as the originator brand] — which it’s probably not, [as that’s] probably overly optimistic — it’s still way out of the reach of most patients if they have [health insurance] coverage problems. Yes, it will help the overall system, but [it will] probably not help the individual patient very much. [I would prescribe biosimilars when they are available] sure, absolutely….You would potentially replace the innovative product with a biosimilar whenever you have that option. The only reason you do that, obviously, is cost. In most cases, it’s not going to be my decision; it’s going to be the decision of whoever is paying for it….It will be helpful, but it’s not going to be a big game-changer….Two thirds of [what is already] a heck of a lot of money is still almost a heck of a lot of money, and most people don’t have that.”

[US] KOL
# Table of Contents

1 Table of Contents ................................................................. 6

1.1 List of Tables ........................................................................... 8

1.2 List of Figures ......................................................................... 9

2 Introduction ............................................................................... 10

2.1 Catalyst .................................................................................. 10

2.2 Related Reports ....................................................................... 11

2.3 Upcoming Related Reports ..................................................... 13

3 Disease Overview ....................................................................... 15

3.1 Etiology and Pathophysiology ............................................... 15

3.1.1 Etiology ............................................................................. 15

3.1.2 Pathophysiology ................................................................. 15

3.2 Symptoms ............................................................................... 19

3.3 Prognosis ............................................................................... 20

3.4 Quality of Life ......................................................................... 20

4 Disease Management ............................................................... 21

4.1 Diagnosis and Treatment Overview ....................................... 21

4.1.1 Diagnosis .......................................................................... 21

4.1.2 Treatment Guidelines ......................................................... 23

4.1.3 Leading Prescribed Drugs for the Treatment of RA ............. 33

4.1.4 Clinical Practice ................................................................. 34

5 Competitive Assessment .......................................................... 40
# Table of Contents

## 5.1 Overview ........................................................................................................................... 40

## 6 Cimzia (certolizumab pegol) ...................................................................................................... 42

### 6.1 Overview ........................................................................................................................... 42

### 6.2 Efficacy ............................................................................................................................. 44

### 6.3 Safety ............................................................................................................................... 44

### 6.4 SWOT Analysis ................................................................................................................. 45

### 6.5 Forecast ............................................................................................................................ 45

## 7 Appendix ................................................................................................................................... 47

### 7.1 Bibliography ...................................................................................................................... 47

### 7.2 Abbreviations .................................................................................................................... 50

### 7.3 Methodology ..................................................................................................................... 53

### 7.4 Forecasting Methodology .................................................................................................. 53

#### 7.4.1 Diagnosed RA Patients ................................................................................................. 53

#### 7.4.2 Percentage of Drug-Treated Patients ............................................................................ 54

#### 7.4.3 General Pricing Assumptions ........................................................................................ 54

#### 7.4.4 Individual Drug Assumptions ......................................................................................... 55

#### 7.4.5 Generic and Biosimilar Erosion ..................................................................................... 55

### 7.5 Primary Research – KOLs Interviewed for This Report ..................................................... 56

### 7.6 Primary Research – Prescriber Survey ............................................................................. 58

### 7.7 About the Authors ............................................................................................................. 59

#### 7.7.1 Analyst .......................................................................................................................... 59

#### 7.7.2 Reviewer ....................................................................................................................... 59

#### 7.7.3 Therapy Area Director .................................................................................................. 60
# Table of Contents

## 7.7.4 Global Head of Healthcare

## 7.8 About GlobalData

## 7.9 Disclaimer

## 1.1 List of Tables

<table>
<thead>
<tr>
<th>Table</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Symptoms of RA</td>
<td>19</td>
</tr>
<tr>
<td>2</td>
<td>1987 ACR Diagnostic Criteria for RA</td>
<td>22</td>
</tr>
<tr>
<td>3</td>
<td>2010 ACR/EULAR Diagnostic Criteria for RA</td>
<td>23</td>
</tr>
<tr>
<td>4</td>
<td>Treatment Guidelines for RA Used by Each Country in the 10MM</td>
<td>26</td>
</tr>
<tr>
<td>5</td>
<td>ACR 2012 Criteria for RA Remission and Low/Moderate/High Disease Activity</td>
<td>29</td>
</tr>
<tr>
<td>6</td>
<td>EULAR 2013 Criteria for RA Remission</td>
<td>30</td>
</tr>
<tr>
<td>7</td>
<td>Most Prescribed Biologics for RA (After csDMARDs) in the Global Markets, 2014</td>
<td>34</td>
</tr>
<tr>
<td>8</td>
<td>Leading Branded Treatments for RA 2014</td>
<td>41</td>
</tr>
<tr>
<td>9</td>
<td>Product Profile – Cimzia</td>
<td>43</td>
</tr>
<tr>
<td>10</td>
<td>Cimzia SWOT Analysis, 2014</td>
<td>45</td>
</tr>
<tr>
<td>11</td>
<td>Global Sales Forecasts ($m) for Cimzia, 2013–2023</td>
<td>46</td>
</tr>
<tr>
<td>12</td>
<td>High-Prescribing Physicians (non-KOLs) Surveyed, By Country</td>
<td>58</td>
</tr>
</tbody>
</table>
Table of Contents

1.2 List of Figures

Figure 1: Normal Synovial Joint and Synovial Joint with RA ................................................................. 16
Figure 2: Cellular and Cytokine Targets for the Current RA Drugs ....................................................... 18
Figure 3: Disease Management Flowchart for Early RA – ACR 2012 ...................................................... 30
Figure 4: Disease Management Flowchart for Established RA – ACR 2012 ............................................. 31
Figure 5: Flowchart for the Management of RA – EULAR 2013 .............................................................. 32
2 Introduction

2.1 Catalyst

The Rheumatoid Arthritis (RA) market will grow over the 2013–2023 forecast period, driven by a number of new product launches, such as:

- Novel biologics
- Anti-interleukin (IL)-6 biologics
- Small molecules, including janus kinase (JAK) inhibitors

Other factors that will drive market expansion are growth in the emerging markets of China, India, and Australia, where product launches extend product lifecycles. In addition, there will be an increase in the prevalence of RA across the 10 major markets (10MM) covered in this report.

The loss of patent protection for the anti-tumor necrosis factor (TNF) marketed brands will allow for the emergence of biosimilars, such as Celltrion’s Remsima (infliximab)/Hospira’s Inflectra (infliximab), which is a Remicade biosimilar. The patent expiries begin in 2015 and 2016, respectively, for the current market leaders:

- J&J’s Remicade
- AbbVie’s Humira

The catalysts and objectives for this report are to:

- Determine the impact that biosimilars will have on the RA market
- Assess the uptake of JAK inhibitors, including Pfizer’s Xeljanz (tofacitinib) and other pipeline agents
- Identify the unmet needs in the RA market
- Determine the remaining opportunities in the RA market
Introduction

2.2 Related Reports

Introduction

- GlobalData (2014). Actemra/RoActemra (Tocilizumab) (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023, December 2014, GDHC498DFR
- GlobalData (2014). Rituxan/MabThera (rituximab) (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023, December 2014, GDHC499DFR
- GlobalData (2014). Sarilumab (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023, December 2014, GDHC504DFR
Introduction

- GlobalData (2014). Denosumab (Prolia) (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023, December 2014, GDHC510DFR
- GlobalData (2014). Decernotinib (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023, December 2014, GDHC513DFR
- GlobalData (2014). Filgotinib (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023, December 2014, GDHC514DFR
- GlobalData (2014). Masitinib (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023, December 2014, GDHC515DFR

2.3 Upcoming Related Reports

Introduction


Appendix

7.8 About GlobalData

GlobalData is a leading global provider of business intelligence in the healthcare industry. GlobalData provides its clients with up-to-date information and analysis on the latest developments in drug research, disease analysis, and clinical research and development. Our integrated business intelligence solutions include a range of interactive online databases, analytical tools, reports, and forecasts. Our analysis is supported by a 24/7 client support and analyst team.

GlobalData has offices in New York, San Francisco, Boston, London, India, Korea, Japan, Singapore, and Australia.

7.9 Disclaimer

All Rights Reserved.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the publisher, GlobalData.